The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Open accessAbstract
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with docetaxel, the combination of nintedanib and docetaxel was associated with a higher incidence of gastrointestinal AEs and transient elevation of liver enzymes [102].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Additional unplanned analyses revealed a pronounced impact on OS in patients with fast-progressing disease and patients who were refractory to first-line chemotherapy.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Unfortunately, survival outcomes remain poor and patients often experience substantial toxicity, underscoring a high unmet need. 8 , 9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 2
- Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
- Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01
Cited by
Sorted by citations
Items 401–500 of 952
Isla, D., de Castro, J., García‐Campelo, R., LIANES, P., Felip, E., Garrido, P., Paz-Ares, L. G., & Trigo, J. M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02191-y · Cited by 17
Matsumoto, K., Shiroyama, T., Kuge, T., Miyake, K., Yamamoto, Y., Yoneda, M., Yamamoto, M., Naito, Y., Suga, Y., Fukushima, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.008 · Cited by 17
Newly developed anti-angiogenic therapy in non-small cell lung cancer
Qu, J., Zhang, Y., Chen, X., Yang, H., Zhou, C., & Yang, N. (2017) · Oncotarget · doi:10.18632/oncotarget.23755 · Cited by 17
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 17
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 16
Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
Wulkersdorfer, B., Zeitlinger, M. A., & Schmid, M. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0302-2 · Cited by 16
Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
Durm, G. A., & Hanna, N. H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.002 · Cited by 16
Aggarwal, C., & Borghaei, H. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0345 · Cited by 16
Zhang, D., Zhang, C., Huang, J., Guan, Y., & Guo, Q. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12898 · Cited by 16
Kai, Y., Matsuda, M., Fukuoka, A., Hontsu, S., Yamauchi, M., Yoshikawa, M., & Muro, S. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13935 · Cited by 16
Prelaj, A., Pircher, C. C., Massa, G., Martelli, V., Corrao, G., Russo, G. L., Proto, C., Ferrara, R., Galli, G., Toma, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13061300 · Cited by 18
Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-01940-y · Cited by 18
Regan, E., Sibley, R. C., Cenik, B. K., Silva, A., Girard, L., Minna, J. D., & Dellinger, M. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150963 · Cited by 16
Bilger, G., Toffart, A.-C., Darrason, M., Duruisseaux, M., Ulmer, L., Wang, P., Leprieur, E. G., Girard, N., Massiani, M. A., Bore, P., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099399 · Cited by 15
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Soo, R. A., Ang, Y. L. E., & Lim, J. S. J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s84356 · Cited by 15
Yu, L., Xu, J., Qiao, R., Zhong, H., Brueckl, W. M., & Zhong, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-260 · Cited by 15
Li, H., Wang, W., Huang, Z., Zhang, P., Liu, L., Sha, X., Wang, S., Zhou, Y. L., & Shi, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1522 · Cited by 16
Clinical development of nintedanib for advanced non-small-cell lung cancer
Okamoto, I., Takeda, M., & Nakagawa, K. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s76646 · Cited by 15
Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm
Chu, B. F., & Otterson, G. A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.020 · Cited by 15
Greillier, L., Tomasini, P., & Barlési, F. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816652083 · Cited by 15
Schliemann, C., Gerß, J., Wiebe, S., Mikesch, J., Knoblauch, N. T. M., Sauer, T., Angenendt, L., Kewitz, T., Urban, M., Butterfaß‐Bahloul, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164499 · Cited by 15
Armoiry, X., Tsertsvadze, A., Connock, M. J., Royle, P., Meléndez‐Torres, G. J., Souquet, P.-J., & Clarke, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199575 · Cited by 15
Visser, S., Hou, J., Bezemer, K., de Vogel, L. L., Hegmans, J. P., Stricker, B. H. C., Philipsen, S., & Aerts, J. G. J. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-5645-x · Cited by 15
Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
Tran, Y. Z., Minozada, R., Cao, X., Johansson, H. J., Branca, R. M., Seashore-Ludlow, B. A., & Orre, L. M. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002036 · Cited by 14
Jin, S., Yang, Y., Ma, Y., Yang, B., Zhang, Y., Kang, S., Zhou, T., Hong, S., Qin, T., Hu, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127306 · Cited by 15
Bosch, M. E., Díez, R. A., Agudo, S. G., & Estela, A. C. (2016) · PubMed · doi:10.7399/fh.2016.40.4.10455 · Cited by 15
Tambo, Y., Hosomi, Y., Sakai, H., Nogami, N., Atagi, S., Sasaki, Y., Kato, T., Takahashi, T., Seto, T., Maemondo, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0435-2 · Cited by 15
Spigel, D. R., Burris, H. A., Greco, F. A., Shih, K. C., Gian, V. G., Lipman, A. J., Daniel, D. B., Waterhouse, D. M., Finney, L. H., Heymach, J. V., et al. (2018) · Cancer · doi:10.1002/cncr.31290 · Cited by 15
Xie, X., Deng, H., Lin, X., Wu, J., Liu, M., Xie, Z., Qin, Y.-Y., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673877 · Cited by 15
Beyond platinum treatment for NSCLC: what does the future hold?
Santarpía, M., Karachaliou, N., & Rosell, R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1288103 · Cited by 15
Gridelli, C., Besse, B., Brahmer, J. R., Crinò, L., Felip, E., & de Marinis, F. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.004 · Cited by 15
Bertaglia, V., Vallone, S., Pacchiana, M. V., & Novello, S. (2017) · Lung Cancer Management · doi:10.2217/lmt-2017-0011 · Cited by 14
Self-citationChen, J.-H., Yang, J.-L., Chou, C., Wang, J., & Hung, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-27994-x · Cited by 14
Sun, M.-Y., & Bhaskar, S. M. M. (2022) · Diagnostics · doi:10.3390/diagnostics12122954 · Cited by 14
Gao, F., You, X., Yang, L., Zou, X., & Sui, B. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2333275 · Cited by 14
Multitarget Inhibitors Derived from Crosstalk Mechanism Involving VEGFR2
Ding, C., Zhang, C., Zhang, M., Chen, Y., Tan, C., Tan, Y., & Jiang, Y. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.112 · Cited by 14
Morabito, A. (2018) · BMC Medicine · doi:10.1186/s12916-018-1011-0 · Cited by 14
Frega, S., Bonanno, L., Guarneri, V., Conte, P., & Pasello, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.013 · Cited by 14
Ma, J., Sun, J., Sun, L., Zhang, S., Huang, L., & Han, C. (2018) · Medicine · doi:10.1097/md.0000000000012083 · Cited by 14
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
Wang, F., Jin, F., Cheng, B., Zhang, Y., Zhou, Q. H., & Wang, S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03752-x · Cited by 14
Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
André, L., Antherieu, G., Boinet, A., Bret, J., Gilbert, T., Boulahssass, R., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14102470 · Cited by 14
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Olmez, O., Bilici, A. E., Gürsoy, P., Çubukçu, E., Sakin, A., Korkmaz, T., Çil, İ., Çakar, B., Menekşe, S., Demir, T., et al. (2022) · Pulmonology · doi:10.1016/j.pulmoe.2022.11.006 · Cited by 14
Barr, M. P., O'Byrne, K. J., Al-Sarraf, N., & Gray, S. G. (2015) · Epigenomics · doi:10.2217/epi.15.51 · Cited by 14
La signalisation FGF/FGFR : implication dans l’oncogenèse et perspectives thérapeutiques
Flippot, R., Kone, M., Magné, N., & Vignot, S. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.04.010 · Cited by 14
Focus on Nintedanib in NSCLC and Other Tumors
Manzo, A., Carillio, G., Montanino, A., Costanzo, R., Sandomenico, C., Rocco, G., & Morabito, A. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00068 · Cited by 14
Awasthi, N., Schwarz, M. A., Zhang, C., & Schwarz, R. E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0489 · Cited by 14
Schulz, C. K. J., Gandara, D. R., Berardo, C. G., Rosenthal, R., Foo, J., Morel, C., Ballinger, M. D., Watkins, C. L., & Chu, P. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.017 · Cited by 14
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14
Self-citationFinal results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial
Capelletto, E., Migliorino, M. R., Morabito, A., Chiari, R., Grossi, F., Tiseo, M., Costanzo, F. D., Delmonte, A., Romano, G. D., Galetta, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.028 · Cited by 14
Self-citationTreatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
Bosch‐Barrera, J., Verdura, S., Ruffinelli, J. C., Carcereny, E., Sais, È., Cuyàs, E., Palmero, R., López‐Bonet, E., Hernández, A., Oliveras, G., et al. (2021) · Cancers · doi:10.3390/cancers13164168 · Cited by 14
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte, G., Passiglia, F., Galvano, A., & Russo, A. G. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1075000 · Cited by 14
Fenchel, K., Dale, S. P., & Dempke, W. C. M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.01 · Cited by 14
Wang, H., Yang, R., Jin, J., Wang, Z., & Li, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259784 · Cited by 16
Krzakowski, M. J., Jassem, J., Antczak, A. J., Błasińska, K., Chorostowska‐Wynimko, J., Dziadziuszko, R., Głogowski, M., Grodzki, T., Kowalski, D. R., Krenke, R., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0022 · Cited by 16
Self-citationAntibody Drug Conjugates in Lung Cancer
Merle, G., Friedlaender, A., Desai, A. P., & Addeo, A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000630 · Cited by 15
Karampitsakos, Τ., Sampsonas, F., Herazo‐Maya, J. D., & Τzouvelekis, Α. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000977 · Cited by 13
Tokhanbigli, S., Haghi, M., Dua, K., & Oliver, B. G. G. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.55 · Cited by 14
Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Lazzari, C., Karachaliou, N., Gregorc, V., Bulotta, A., González‐Cao, M., Verlicchi, A., Altavilla, G., Rosell, R., & Santarpía, M. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1326822 · Cited by 13
Gerber, D. E., Swanson, P. M., López-Chávez, A., Wong, L., Dowlati, A., Pennell, N. A., Cronier, D. M., Qin, A., Ilaria, R. L., Cosaert, J. G. C. E., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.009 · Cited by 13
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Xu, Y. D., Liu, Y., He, T., Zhang, Y., Wang, M., Yuan, H., & Yang, M. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112020 · Cited by 13
Hegedüs, L., Szücs, K. D., Kudla, M., Heidenreich, J., Jendrossek, V., Peña‐Llopis, S., Garay, T., Czirók, A., Aigner, C., Plönes, T., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.852812 · Cited by 12
Novel Therapies for Advanced Squamous Cell Carcinoma of the Lung
Koutsoukos, K., & Mountzios, G. (2016) · Future Oncology · doi:10.2217/fon.15.358 · Cited by 13
Nintedanib in Advanced NSCLC: Management of Adverse Events
Lemmens, L. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.33 · Cited by 13
Dai, W., Luo, B., Wu, Z., Chen, J., Feng, G., & Guan, P. (2015) · Europe PMC (PubMed Central) · Cited by 13
Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer
Martínez, M. C. R., Sánchez, A., & García‐Carbonero, R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385762 · Cited by 14
Ambade, A. S., Jung, B., Lee, D., Doods, H. N., & Wu, D. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.010 · Cited by 13
Rybarczyk-Kasiuchnicz, A., & Ramlau, R. (2018) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2018.76478 · Cited by 14
Reck, M., Kerr, K. M., Grohé, C., Manegold, C., Pavlakis, N., Paz-Ares, L. G., Huber, R. M., Popat, S., Thatcher, N., Park, K., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0948 · Cited by 13
Self-citationEmerging angiogenesis inhibitors for non-small cell lung cancer
Malapelle, U., & Rossi, A. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1619696 · Cited by 13
Song, M. J., Kim, D. J., Paik, H. C., Cho, S., Kim, K., Jheon, S., Lee, S. H., & Park, J. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235126 · Cited by 13
Boichuk, S., & Gessel, T. (2025) · Cancers · doi:10.3390/cancers17203354 · Cited by 12
Divan, H. A., Bittoni, M. A., Krishna, A., & Carbone, D. P. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107177 · Cited by 12
Pan, H., Lee, C.-W., Wu, L., Hsu, H., Tung, Y., Liao, W., & Lee, C. (2023) · APL Bioengineering · doi:10.1063/5.0115464 · Cited by 12
Nintedanib Plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
Ikeda, S., Ogura, T., Kato, T., Kenmotsu, H., Agemi, Y., Tokito, T., Ito, K., Isomoto, K., Takiguchi, Y., Yoneshima, Y., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202311-941oc · Cited by 13
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
Ke, K., Li, H., Yao, H., Shi, X., Dong, C., Zhu, Y., Liu, X., Li, L., Leung, K., Wong, M., et al. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12872 · Cited by 12
Zugazagoitia, J., Díaz, A., Jiménez, E., Nuñez, J. A., Iglesias, L., Ponce-Aix, S., & Paz-Ares, L. G. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00036 · Cited by 12
Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments
Sase, K., Fujisaka, Y., Shoji, M., & Mukai, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00869-6 · Cited by 13
Corke, L., & Sacher, A. G. (2021) · Current Oncology · doi:10.3390/curroncol29010004 · Cited by 15
Yang, M., Zhao, X., Li, B., Wang, Y., & Shi, X. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220629154619 · Cited by 12
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
Bearz, A., Carlo, E. D., Conte, A. D., Spina, M., Ros, V. D., Bertoli, E., Revelant, A., Stanzione, B., & Tirelli, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137322 · Cited by 12
Franco, A. O., Hodgson, C., Raja, H., Carter, M., Lindsay, C. R., Hughes, S., Cove-Smith, L., Taylor, P. D., Summers, Y., Blackhall, F. H., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00889-8 · Cited by 12
To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Basu, D., Pal, R., Sarkar, M., Barma, S., Halder, S., Roy, H., Nandi, S., & Samadder, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266261150231110053650 · Cited by 12
Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects
Bargagli, E., Bonti, V., Ferrari, K., Rosi, E., Bindi, A., Bartolucci, M., Moroni, C., & Voltolini, L. (2017) · In Vivo · doi:10.21873/invivo.11130 · Cited by 13
Saudi lung cancer management guidelines 2017
Jazieh, A. R., Kattan, K. A., Bamousa, A., Olayan, A. A., Abdelwarith, A., Ansari, J., Al-Twairqi, A., Alfayea, T. M., Saleh, K. A., Husaini, H. A., et al. (2017) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_92_17 · Cited by 12
Wu, F., Zhang, S., Gao, G., Zhao, J., Ren, S., & Zhou, C. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414757 · Cited by 12
Ikeda, S., Kato, T., Ogura, T., Sekine, A., Oda, T., Masuda, N., Igawa, S., Katono, K., Otani, S., Yamada, K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4150-y · Cited by 12
Spagnuolo, A., Palazzolo, G., Sementa, C., & Gridelli, C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1713092 · Cited by 12
Nintedanib-induced glomerular microangiopathy: a case report
Hasegawa, M., Uehara, A., Suzuki, T., Sekine, R., Yazawa, M., Ichikawa, D., Koike, J., & Shibagaki, Y. (2020) · CEN Case Reports · doi:10.1007/s13730-020-00474-w · Cited by 13
Yu, Z., Cai, X., Xu, Z., He, Z., Lai, J., Wang, W., Zhang, J., Kong, W., Huang, X., Chen, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0519 · Cited by 12
Lin, Y., Su, W., & Lan, G. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23338 · Cited by 12
RetractedLi, B. T., Barnes, T. A., Chan, D. L. H., Naidoo, J., Lee, A., Khasraw, M., Marx, G. M., Kris, M. G., Clarke, S. J., Drilon, A. E. D. C., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.004 · Cited by 12
Pu, X., Xiao, Z., Li, J., Wu, Z., Ma, Z., Weng, J., Xiao, M., Chen, Y., Cao, Y., Cao, P., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107538 · Cited by 11
Yamaguchi, T., Shimizu, J., Shigematsu, F., Watanabe, N., Hasegawa, T., Horio, Y., Inaba, Y., & Fujiwara, Y. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-45 · Cited by 11
Daum, S., Decristoforo, L., Mousa, M., Salcher, S., Plattner, C., Hosseinkhani, B., Trajanoski, Z., Wolf, D. G. F., Carmeliet, P., & Pircher, A. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02221-6 · Cited by 12
Nintedanib for the treatment of patients with advanced non-small-cell lung cancer
Reck, M., Heigener, D. F., & Reinmuth, N. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.945430 · Cited by 11
Self-citation
Metadata
- Authors
- Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
- Affiliations
- German Center for Lung Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Herlev Hospital (DK)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Meir Medical Center (IL)
- Dnipro State Medical University (UA)
- Shanghai Jiao Tong University (CN)
- Boehringer Ingelheim (United States) (US)
- University of Turin (IT)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 143-155
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2170030318
- Cited by
- 951
- References
- 36
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
- FWCI
- 98.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
- MeSH terms
- Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
